Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

[1]  T. Kipps,et al.  Targeted Therapy in Chronic Lymphocytic Leukemia , 2019, Cancer journal.

[2]  M. Hallek,et al.  Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? , 2019, HemaSphere.

[3]  Jeffrey A Jones,et al.  Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center , 2017 .

[4]  P. Jain,et al.  Ibrutinib: A Risk Factor for Invasive Fungal Infections? , 2017 .

[5]  C. Nabhan,et al.  Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy , 2017 .

[6]  S. Colucci,et al.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes. , 2017, Blood.

[7]  Jennifer H. Lin,et al.  Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL , 2017, Leukemia.

[8]  M. Hallek,et al.  FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia , 2017, Leukemia & lymphoma.

[9]  J. Byrd,et al.  Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) , 2016 .

[10]  K. Babu,et al.  Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL , 2016, Acta oncologica.

[11]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[12]  J. Byrd,et al.  Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients , 2015 .

[13]  K. Rezvani,et al.  Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions , 2015 .

[14]  G. Marti,et al.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. , 2015, Blood.

[15]  A. Rosenwald,et al.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.

[16]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[17]  Jeffrey A Jones,et al.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.

[18]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[19]  D. Catovsky,et al.  Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial , 2012, Leukemia & lymphoma.

[20]  A. Stone,et al.  Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) questionnaire , 2011, Supportive Care in Cancer.

[21]  Ohidul Siddiqui,et al.  Statistical Methods to Analyze Adverse Events Data of Randomized Clinical Trials , 2009, Journal of biopharmaceutical statistics.

[22]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[23]  Deborah A. Bowen,et al.  Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients , 2007, British journal of haematology.

[24]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[25]  M. Hallek,et al.  Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Greil,et al.  Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr , 2004, European journal of haematology.

[27]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[28]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[29]  J. Coebergh,et al.  Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands , 2014, Annals of Hematology.

[30]  Jeffrey A Jones,et al.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.